Market entry · Product integrity
Reducing the falsified medicine risk when you enter a new market
A manufacturer reduces falsified medicine risk in a new market by shipping only to an importer the national regulatory authority has authorised, only products authorised there, with complete documentation for every consignment. WHO Technical Report Series No. 1019, Annex 5, describes the border controls, document checks and packaging examination that then help customs and regulators detect falsified product.
Why does falsified medicine risk matter when you enter a new market?
Because a new market is where your supply chain is least familiar to you. WHO Technical Report Series No. 1019, Annex 5, Guidelines on import procedures for medical products (2019), says medical products should not be treated like ordinary commodities, and that their distribution must be rigorously controlled to prevent the infiltration of substandard and suspected falsified medical products into the supply system.1
The guideline is precise about terms. Falsified medical products are those that deliberately or fraudulently misrepresent their identity, composition or source, including any substitution, adulteration or reproduction of an authorized product. A substandard product, by contrast, is an authorized product that fails its quality standards, its specifications, or both.1 The guideline refers to the national regulatory authority as the NRA.1
How does WHO risk-based border control reduce the risk?
By aiming controls where the risk is, rather than reacting after the fact. Paragraph 1.3 of Annex 5 calls for a departure from the traditional reactive control system to a risk-based and proactive approach. A country's risk-based surveillance scheme should identify risks and define the controls that protect patients from substandard, falsified and unregulated medical products.1
Paragraph 5.3 adds that NRAs should collaborate closely with customs, police, the judiciary and others to detect substandard and falsified products and to avoid their import.1
How do you verify an authorised importer?
Check the importer and the product against what the NRA has authorised. Paragraph 5.2 says the NRA should publish an updated list of authorized medical products and authorized importers permitted to import into the country for marketing, and that in all cases close collaboration with the NRA is needed to verify that the product is authorized for importation and that there are no restrictions, temporary suspensions or withdrawals of marketing authorizations.1
For an exporter, this is the most useful control in its own hands. For how that relationship is usually structured, see authorised importers and local agents, and for vetting a partner more broadly, see qualifying a distributor.
What falsified medicine documentation should travel with each consignment?
Enough to tie the shipment to an authorised importer, an authorised product and a specific batch. Paragraph 6.1 of Annex 5 says that, as a prerequisite to customs clearance, the importing agency or agent should furnish the required documentation for each consignment, for example:1
- documents issued by the NRA in the importing country attesting that the importer is duly authorized to import the medical products, and that the product is duly authorized to be marketed or permitted to be imported;
- a batch-release certificate issued by the manufacturer;
- a safety data sheet, where applicable;
- a relevant invoice, bill or delivery slip for the batch, including the product name, batch number, quantity and expiry date;
- any other documentation required by national or regional legislation for customs clearance, for example a certificate in accordance with the WHO Certification Scheme; and
- any other document that should be issued by the competent authority of the exporting country, as applicable.
Getting the batch-release certificate and batch-level invoice right on every shipment is common practice that makes a genuine consignment easy to recognise. For the certificate under the WHO Certification Scheme, see the certificate of a pharmaceutical product.
What do customs check when the shipment arrives?
The size of the consignment, the paperwork and the packaging. Paragraph 7.1 says visual examination and preliminary screening technologies should be routinely undertaken by the customs authorities, where possible with an NRA inspector or enforcement officer. The size of the consignment should be checked against invoices, bills or delivery slips, attention should be given to the nature and conditions of the packaging and labelling, and the external package should be compared with a standard when this is possible.1
The same paragraph notes that spelling errors, low-quality printing and other defects may be signs of a substandard or falsified product, and that the external package should be intact, without signs of damage or infiltration that may change the inner content.1 Consistent, well printed packaging therefore works in the manufacturer's favour. For how containers and labels are usually prepared, see packaging and labelling an export shipment.
What happens when falsified product is found?
It is removed from the market and reported. Paragraph 7.6 says falsified medical products and other products imported in contravention of the law must be forfeited and destroyed, or otherwise dealt with under the procedures established by national and regional legislation, with the records appropriately archived.1 Annex 5 also says NRAs should notify other national or regional authorities and the WHO Global Surveillance and Monitoring System of confirmed cases of imported substandard or falsified products, without delay, on the appropriate form.1
How does this apply to the Republic of Yemen?
The WHO framework above is the international baseline, not a country checklist. Local specifics for a particular product are confirmed case by case. For the wider market picture, see entering the Yemen market and import controls and clearance. Readers in Yemen who want to recognise suspect product on the shelf can read our Arabic guide to falsified and substandard medicines.
Frequently asked questions
How can a manufacturer reduce the risk of falsified medicines when entering a new export market?
Ship only to an importer the national regulatory authority has authorised, only products authorised for that market, and send complete documentation with every consignment. WHO Technical Report Series No. 1019, Annex 5, describes how the authority, customs and the importer then check authorisation, paperwork and packaging, which helps detect falsified product and keep it out.
What is a falsified medical product?
WHO Technical Report Series No. 1019, Annex 5, defines falsified medical products as those that deliberately or fraudulently misrepresent their identity, composition or source, including any substitution, adulteration or reproduction of an authorised product. Intellectual property considerations fall outside the definition. A substandard product is different: an authorised product that fails its quality standards or specifications.
How does a manufacturer check that an importer is authorised?
WHO Technical Report Series No. 1019, Annex 5, says the national regulatory authority should publish an updated list of authorised medical products and authorised importers. It also calls for close collaboration with the authority to confirm the product is authorised for importation and has no restrictions, temporary suspensions or withdrawals of its marketing authorisation.
What happens to falsified medicines found at the border?
Under WHO Technical Report Series No. 1019, Annex 5, falsified products and other products imported in contravention of the law must be forfeited and destroyed, or dealt with under national or regional procedures, with records archived. Authorities should notify confirmed cases without delay to other authorities and to the WHO Global Surveillance and Monitoring System.
References
- World Health Organization, Guidelines on import procedures for medical products, WHO Technical Report Series No. 1019, Annex 5 (2019), sections 1, 3, 5, 6 and 7. Accessed 23 October 2026. cdn.who.int